News Channels

05 Apr 2019 U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
05 Apr 2019 Nanobiotix announces first ever radioenhancer to receive European market approval
05 Apr 2019 Fresenius Kabi Receives European Commission Approval For Adalimumab Biosimilar IDACIO
04 Apr 2019 EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
04 Apr 2019 Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study
04 Apr 2019 Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug
04 Apr 2019 VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
04 Apr 2019 Janssen Announces Investigational CAR-T Therapy JNJ-68284528 Granted PRIME Designation by the European Medicines Agency
04 Apr 2019 Further record year of biologics sales in 2018 due to innovative antibodies
03 Apr 2019 Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment
03 Apr 2019 AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166
03 Apr 2019 Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
03 Apr 2019 Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE™ Significantly Outperforms Current Prediction Methods
03 Apr 2019 Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
03 Apr 2019 Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
03 Apr 2019 Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
03 Apr 2019 Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
03 Apr 2019 Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
03 Apr 2019 Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
03 Apr 2019 FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up